BioLineRx Ltd. (BLRX) — SEC Form D Filing
BioLineRx Ltd. (BLRX) filed an SEC Form D on September 9, 2026, reporting $3.75M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 9, 2026
- Amount reported
- $3.75M
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://biolinerx.com/
What the company does
Exemption: Rule 506(b). Incorporated: ISRAEL
Problem
Patients suffer from certain cancers, rare diseases, and devastating conditions like pancreatic ductal adenocarcinoma (PDAC), for which there is a significant unmet medical need for effective treatments.
Solution
BioLineRx develops life-changing therapies, including GLIX1, an oral small molecule targeting the DNA damage response in cancer cells, and a PDAC program, to provide meaningful therapeutic benefits to patients.
Why now
Advances in understanding complex diseases like cancer and rare genetic disorders, combined with innovations in drug discovery and clinical development methodologies, create an opportune time for focused therapeutic development.
Verdict
Investors backed a targeted therapeutic approach to high-unmet-need diseases like PDAC, not a platform technology with broad applicability. This cleared because the narrative presented a clear path to de-risking specific assets within a known regulatory framework, emphasizing execution over novel science. Investors were implicitly betting on the team's ability to navigate clinical trials and demonstrate efficacy for GLIX1 and the PDAC program, which would then attract larger pharma partners. This limited upside to the value of individual drug assets rather than creating a diversified portfolio or breakthrough modality.
Source: SEC EDGAR Form D filing